Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
March 07, 2024 07:30 ET
|
Mustang Bio, Inc.
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively ~70% improvement in...
Propulsion of Glioma Clinical Trial Pipeline as Novel and Extensive 220+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
May 17, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 17, 2023 (GLOBE NEWSWIRE) -- Propulsion of Glioma Clinical Trial Pipeline as Novel and Extensive 220+ Therapies Likely to Enter in the Treatment Domain | DelveInsight The glioma...
FLAG Therapeutics Receives Rare Pediatric Disease (RPD) Designation for FLAG-003 for the Treatment of Children with Diffuse Intrinsic Pontine Glioma (DIPG)
January 31, 2023 13:00 ET
|
Flag Therapeutics, Inc.
RALEIGH, N.C., Jan. 31, 2023 (GLOBE NEWSWIRE) -- FLAG Therapeutics, Inc., announced today that FLAG-003, an investigational small molecule therapy for the treatment of Diffuse Intrinsic Pontine...
Canadian Brain Cancer Patients Treated Unequally: Brain Cancer Canada
October 26, 2022 08:30 ET
|
Brain Cancer Canada
TORONTO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- For Canadians diagnosed with brain cancer, where they live determines how much access they have to treatment, according to new research by the charity...
Brain Cancer Canada funds Canada's first genomics technology for rapid and precise brain tumour diagnostics
May 01, 2022 09:00 ET
|
Brain Cancer Canada
TORONTO, May 01, 2022 (GLOBE NEWSWIRE) -- Today marks the first day of Brain Cancer Awareness month. On this day Brain Cancer Canada grants $100,000 to the St. Michael's Hospital program to acquire...
Brain Cancer Canada To Fund Barrier Breaking Chemistry Research Targeting Glioblastoma
November 30, 2021 08:30 ET
|
Brain Cancer Canada
TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- A pioneering approach led by Prof. Patrick Gunning at the University of Toronto, leveraging advanced medicinal chemistry to help develop potential...
Brain Cancer Canada Funds Canadian Research Aiming To Treat Brain Cancer
October 24, 2021 09:00 ET
|
Brain Cancer Canada
TORONTO, Oct. 24, 2021 (GLOBE NEWSWIRE) -- Brain Cancer Canada has issued a $100,000 grant to Canadian research exploring new frontiers of brain cancer treatment. Drs. Cynthia Hawkins and Roman...
T.J. Stalvey Joins NX Development Corp. (NXDC) as Vice President of Clinical Development and Medical Affairs
April 15, 2021 10:00 ET
|
NX Development Corp.
Lexington, KY, April 15, 2021 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life-sciences company wholly owned by photonamic GmbH & Co. KG., today announced that Tracy Jerome “T.J.” ...
Lexington-Based NX Development Corp (NXDC) Announces Baptist Health Lexington is First Hospital in Kentucky to Use Breakthrough Imaging Agent for Brain Tumor Visualization
October 03, 2019 12:58 ET
|
NX Development Corp.
Lexington, KY, Oct. 03, 2019 (GLOBE NEWSWIRE) -- NX Development Corp (NXDC), a life sciences company based in Lexington, KY, today announced Baptist Health Lexington is the first hospital in state...
Oncotelic Reports that It's Proprietary In-Situ Cancer Vaccine Improved Survival over Standard Chemotherapy in Patients with Recurrent Metastatic Pancreas Cancer and Recurrent High Grade Glioma
February 13, 2019 09:15 ET
|
Oncotelic Inc
Phase 2 Clinical Data Presented at 11th AACR-JCA Joint Conference on Breakthroughs in Cancer Research:Biology to Precision MedicineOT-101 exhibited promising single agent clinical activity as second...